A Phase 4 interventional study of Meropenem in Sepsis, sponsored by Pfizer. Completed at 12 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing meropenem in Sepsis — 4 open to participants now, 5 under way, 1 of them phase 3. Meropenem · Sepsis.
Among the 16 studies testing meropenem in Sepsis, this one is the 9th largest by enrollment, is the only one that started in 2002, is one of 7 in phase 4, and was the 1st registered.
2,418 studies on the registry are indexed under Sepsis; 542 are open to participants now.
Browse Sepsis studies →4 of the 16 studies testing meropenem in Sepsis are open now, in 12 countries. Recruiting first, the newest first:
Hellenic Institute for the Study of Sepsis · Sites in Greece
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Scandinavian Critical Care Trials Group · Sites in Denmark
Ages 18+
National University of Singapore · Sites in Australia, China, Lebanon and 9 more countries
Ages 18+
By country, each count listing its studies:
Meropenem: first FDA approval 1996 (MERREM IV), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7 · Phase 4 7
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 102 across 1,166 interventional studies indexed under Sepsis.
Median enrollment 190 across the 16 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing meropenem in Sepsis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
Exclusion Criteria:
-
Number of days from randomization to recovery from sepsis among those patients who survived the trial period
Endpoint considered in conjunction with observed mortality rates to determine whether any reduction in time to recovery from sepsis
Number of days from randomization to ready to discharge from the ICU
Number of days from randomization until patient is discharged from the ICU
Number of days on first line antibiotic therapy
Number of days from randomization until patient is discharged from hospital
Proportion of patients who achieve clinical cure from sepsis following first line antibiotic therapy
Proportion of all patients who are ready to discharge from the ICU following antibiotic therapy
Mortality rate due to "all causes" in the meropenem group and the standard antibiotic therapy group
Mortality rate due to infection in the meropenem group and the standard antibiotic therapy group
Health Economics-Resource utilization for main treatment and diagnostic procedures, tools and materials
The record gives a start of Jan 2002, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meropenem